Tenax Therapeutics, Inc. (TENX) is a publicly traded Healthcare sector company. As of May 21, 2026, TENX trades at $11.85 with a market cap of $308.22M and a P/E ratio of -8.85. TENX moved +4.49% today. Year to date, TENX is -2.60%; over the trailing twelve months it is +100.00%. Its 52-week range spans $3.25 to $18.38. Analyst consensus is strong buy with an average price target of $31.50. Rallies surfaces TENX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tenax Completes Randomization of 230 Patients, Extends Cash Runway to 2028: Tenax completed randomization of over 230 patients in its Phase 3 LEVEL trial of oral levosimendan and now expects topline data in third quarter 2026. The company reported $118.8 million in cash, extending its runway through early 2028, and posted a $15.7 million net loss driven by higher R&D spending.
| Metric | Value |
|---|---|
| Price | $11.85 |
| Market Cap | $308.22M |
| P/E Ratio | -8.85 |
| EPS | $-1.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.38 |
| 52-Week Low | $3.25 |
| Volume | 1.01K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-52.60M |
| Gross Margin | 0.00% |
5 analysts cover TENX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $31.50.